Tulane is actively seeking commercial entities to further develop and commercialize a novel formulation of peptide and protein conjugates of Tacrolimus-32-Thiol
This targeted approach is superior for rheumatoid arthritis, organ transplantation, and autoimmune diseases. Our product has higher stability, featuring conjugates having a cleavable linker to prevent the release of therapeutic or cytotoxic agents in circulation. More specific and less toxic because it has an affinity for activated T-cells. 17-day half-life in humans thus enabling drug release over a two-week period.
In vitro and in vivo proof-of-concept data has been obtained.